2.04 The critical accounting estimates give no sensitivity for the sales-deduction accruals, the [product] and [product] intangible assets or the tax valuation allowance: is that information immaterial or not reasonably available?
Company G · a US-listed specialty pharmaceutical company · SEC-style question
In brief
Regulation S-K asks each critical accounting estimate to show, to the extent material and reasonably available, how sensitive the reported amount is to its key assumptions. None of the estimates in Management's Discussion and Analysis (MD&A) gives any sensitivity: not the sales-deduction accruals, whose [product] Medicaid utilization assumption is the auditor's critical audit matter (CAM); not the [amount] [product] and [amount] [product] intangible assets; not the deferred-tax valuation allowance. For scale, one percentage point of 2025 gross product sales is about [n] (US$ thousands), 8.74% of the pre-tax loss. The rule's qualifier leaves room for management's view, so this is put as a question. The 2024 Form 10-K had the same gap.
The evidence, as filed
8 further page extracts: screenshot withheld to protect the company’s identity. The rows below say what each shows.
What the filing shows, and what the rule requires
| What the filing shows | What the rule requires |
|---|---|
The estimates describe methods and give deduction rates of [n]%, [n]% and [n]% for three years, but no sensitivity of any estimate; the intangible-asset estimate says only that the carrying value is recoverable; the tax estimate says only that a change would be material. | For each estimate, the effect of a reasonably possible change in its key assumption (for example the Medicaid utilization or rebate rate on revenue and the accrual; the margin by which the [product] and [product] assets pass the recoverability test; the deferred-tax assets that depend on forecast income), or a statement of why that information is not material. |
The rule
Regulation S-K Item 303(b)(3)
This information should include why each critical accounting estimate is subject to uncertainty and, to the extent the information is material and reasonably available, how much each estimate and/or assumption has changed over a relevant period, and the sensitivity of the reported amount to the methods, assumptions and estimates underlying its calculation.
Version: In force from [date] · Source: Regulation S-K, 17 CFR 229.303 (as amended by Release 33-10890, effective [date]; eCFR text)
Regulation S-K Item 303(b), Instruction 3
For critical accounting estimates, this disclosure must supplement, but not duplicate, the description of accounting policies or other disclosures in the notes to the financial statements.
Version: In force from [date] · Source: Regulation S-K, 17 CFR 229.303 (as amended by Release 33-10890, effective [date]; eCFR text)
Why it applies here. Item 303(b)(3) has three limbs - why the estimate is uncertain, how much it has changed, and the sensitivity of the reported amount - the last two qualified by 'to the extent the information is material and reasonably available'. The estimates as written give the first limb, and most of their text is their own rather than a copy of the policy note, so Instruction 3 (supplement, not duplicate) is not the issue here. Whether the qualifier excuses the missing sensitivity depends on facts only management holds: the size of a reasonably possible change in the utilization percentage, and the margins in the recoverability and valuation-allowance assessments. The data appear to be available, because the auditor tested the utilization percentage against an independently developed range. The change limb is carried by 2.07; this point is the missing sensitivity.
Why it matters
Readers cannot judge how far revenue, the [amount] of tested intangible assets or the tax benefit could move if the key assumptions change, which is the purpose of the critical-estimate disclosure.
How often the SEC staff raises this. In 1,100 SEC staff comment letters on fiscal 2023 and 2024 Forms 10-K, released January 2025 to October 2026, critical accounting estimates drew 23 of the 1,774 numbered comments (1.3%): topic 16 of 25 by frequency.
The SEC staff has raised this with other companies
The staff asked Arcutis Biotherapeutics for the effect of reasonably likely changes in its gross-to-net accrual assumptions, and Babcock & Wilcox for how much each critical estimate changed and its sensitivity.
Exposure
None until management answers; if the sensitivity is material, a staff comment asking for quantified sensitivity and a future-filings undertaking. No restatement.
Our workings
MD&A lists three critical accounting estimates beyond goodwill - [wording masked], the valuation and impairment of intangible assets, and income taxes (printed pages 101-104). Each explains why it is uncertain. None gives a sensitivity. The auditor's report names one critical audit matter, the [product] Medicaid rebate accrual, and identifies the single assumption that drives it: the sales utilization percentage. The intangible-asset estimate covers the [amount] [product] and [amount] [product] assets; [product] sales fell 10% in 2025 to [n] (US$ thousands). The tax note shows that, as part of the overall change in valuation allowance, the company recognized a net income tax benefit of [amount] in 2025.
gross product sales were [n] + [n] = [n]; one percentage point of that is [n], which is 8.74% of the absolute 2025 pre-tax loss of [n] (extra workings). This is a measure of scale, not a reasonably possible change that management has estimated.
| Critical accounting estimate | Why uncertain | How much it changed | Sensitivity |
|---|---|---|---|
| [wording masked] (rebates, returns, chargebacks, fees) | Given (printed pages 101-102) | Partial: rates by year; prior-year true-up not quantified | Absent |
| Goodwill (single reporting unit) | Given (p.103) | Not applicable | Partial: 'significantly exceeded', no measure |
| Finite-lived intangible assets ([product], [product]) | Given (p.104) | Absent | Absent |
| Income taxes and valuation allowance | Given (p.104) | Absent in MD&A (note only) | Absent |
| Step | Computation | Result |
|---|---|---|
| Gross product sales 2025 | [n] + [n] = [n] | [n] |
| Deduction rate (company's method) | [n] / [n] = 26.74% | 26.74% (printed [n]%) |
| One percentage point of gross product sales | [n] x 1% = [n] | [n] |
| Share of absolute 2025 pre-tax loss | [n] / [n] = 8.74% | 8.74% |
| Intangible assets tested (US$ billion) | [n] + [n] = [n] of [n] finite-lived | [n] |
Management’s best defense, and our reply
Management would say the rule asks for sensitivity only to the extent material and reasonably available, that the rebate accrual is built from many program-level assumptions, and that in the 2024 Form 10-K the prior-year true-ups were described as immaterial, so the estimate has historically proved accurate and its sensitivity is not material. On intangibles and tax it would say the recoverability margins are wide and the tax note explains the valuation allowance in full. That defense is tenable on the rule's words: the one-point figure here is a measure of scale, not a reasonably possible change, and only management knows the true range. Against it, the auditor isolated one driving assumption and built a range for it, so the data exist, and the 2025 filing no longer calls the true-ups immaterial; the point is therefore put to management as a question rather than stated as a breach.
The fix
- Either add one quantified sentence per estimate (for example: 'A one percentage point change in the [product] Medicaid utilization rate would change 2025 net product sales by approximately $X million'; 'estimated undiscounted cash flows exceeded the carrying amount of the [product] intangible asset by approximately X%'), or state that a reasonably possible change would not have a material effect.
Question for the company
For the sales-deduction accruals (in particular the [product] Medicaid sales utilization percentage), the [product] and [product] intangible assets and the deferred-tax valuation allowance, what is the effect on the reported amounts of a reasonably possible change in the key assumption, and on what basis did management conclude that this sensitivity was not material or not reasonably available for the 2025 and 2024 Forms 10-K?
Evidence relied on
| # | What it shows | Type | Where |
|---|---|---|---|
| 1 | The sales-deduction estimate gives rates by year but no sensitivity | Document | Form 10-K 2025, page 101 |
| 2 | 2025 provision for sales deductions used in the gross-sales computation | Document | Form 10-K 2025, page 101 |
| 3 | 2025 net product sales used in the gross-sales computation | Document | Form 10-K 2025, page 92 |
| 4 | The rebate estimate ends with a generic caution instead of a sensitivity | Document | Form 10-K 2025, page 102 |
| 5 | The auditor's critical audit matter (page F-1) isolates one driving assumption, so its sensitivity is available | Document | Form 10-K 2025, financial-statement pages (printed F-n; see folios) |
| 6 | Intangible-asset estimate: the [product] asset | Document | Form 10-K 2025, page 104 |
| 7 | Intangible-asset estimate: the [product] asset, said only to be recoverable | Document | Form 10-K 2025, page 104 |
| 8 | [product] sales fell 10% in 2025, the kind of trend a recoverability sensitivity should address | Document | Form 10-K 2025, page 92 |
| 9 | The tax estimate states only that changes would be material, with no quantification | Document | Form 10-K 2025, page 104 |
| 10 | Tax note (page F-47) shows the valuation-allowance estimate moved materially in the year | Document | Form 10-K 2025, financial-statement pages (printed F-n; see folios) |
| 11 | 2025 pre-tax loss used as the materiality benchmark (statement of income, page F-4) | Document | Form 10-K 2025, financial-statement pages (printed F-n; see folios) |
| 12 | The 2024 Form 10-K gave the same intangible-asset estimate without any sensitivity | Document | Form 10-K 2024 (prior year), page 99 |
| 13 | The fiscal 2024 sales-deduction estimate gives the amounts and rates for three years only, with no effect of a change in the key assumption | Document | Form 10-K 2024 (prior year), page 97 |
| 14 | The rebate estimate acknowledges that actual experience may differ but quantifies nothing | Document | Form 10-K 2024 (prior year), page 97 |
| 15 | The intangible-asset estimate gives only the conclusion, with no margin by which the assets pass the recoverability test | Document | Form 10-K 2024 (prior year), page 99 |
| 16 | The tax estimate says a change would be material but gives no amount dependent on forecast income | Document | Form 10-K 2024 (prior year), page 100 |
Absence check
- Document
- Form 10-K 2025
- Where it would appear
- Rebates
- What is missing
- the sensitivity of the rebate and other sales-deduction accruals to the utilization and rebate-rate assumptions
- Pages looked at
- p.101-104 (critical accounting estimates); p.119-120 (auditor's report); p.127-134 (Note 2)
- Result
- 'sensitivity' hits only product indications ('hypersensitivity', p.11, [n]) and a privacy risk factor; 'hypothetical' hits only Item 7A market risk; 'percentage point' and 'reasonably possible change' do not hit.
Absence check
- Document
- Form 10-K 2025
- Where it would appear
- As of [date], we had [amount]
- What is missing
- any measure of the margin by which the [product] and [product] assets passed the recoverability test, or the change in assumptions that would cause an impairment
- Pages looked at
- p.103-104 (intangible-asset estimate); p.139-140 (Note 9)
- Result
- 'headroom', 'percentage point' and 'reasonably possible change' do not hit; 'sensitivity' hits only product indications and a privacy risk factor, as above.
Absence check
- Document
- Form 10-K 2024 (prior year)
- Where it would appear
- Rebates
- What is missing
- the effect on revenue and on the accrual of a reasonably possible change in the rebate or utilization rate
- Pages looked at
- Form 10-K 2024 (prior year) p.96-100 (critical accounting estimates, page images)
- Result
- 'sensitivity' hits only inside 'hypersensitivity' in product indications; 'hypothetical' hits only in the market-risk item for interest-rate and currency exposures; 'percentage point', 'reasonably possible change' and 'headroom' have no hits
Absence check
- Document
- Form 10-K 2024 (prior year)
- Where it would appear
- Impairment of Intangible Assets
- What is missing
- the margin by which the [product] and [product] assets pass the recoverability test, or the change in assumptions that would cause an impairment
- Pages looked at
- Form 10-K 2024 (prior year) p.98-100 (page images)
- Result
- 'sensitivity' hits only inside 'hypersensitivity' in product indications; 'hypothetical' hits only in the market-risk item; 'percentage point', 'reasonably possible change' and 'headroom' have no hits
Prepared by Pramanex from the company’s public SEC filings, without the company’s involvement, to show how a 10-K Pre-filing Check reads. The company is not named, and nothing on this page is a statement about any identifiable company. Observations are not an audit, review or other attestation or assurance engagement, and not legal advice. An SEC-style question is a question, not a conclusion.
Want this on your own 10-K, before you file?
Start with three free findings on your latest 10-K, or book a fixed-price 10-K Pre-filing Check.
Your next 10-K will be in draft before the audit is done.
Have it read before you file.
Start with three free findings on your latest 10-K, or book a fixed-price 10-K check. Drafts only under NDA, inside your insider trading policy.